Free Trial

Evolus (EOLS) Stock Price, News & Analysis

Evolus logo
$6.48 +0.24 (+3.77%)
As of 02:26 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Evolus Stock (NASDAQ:EOLS)

Advanced

Key Stats

Today's Range
$6.24
$6.55
50-Day Range
$5.77
$9.53
52-Week Range
$5.71
$17.82
Volume
408,386 shs
Average Volume
1.08 million shs
Market Capitalization
$418.80 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.25
Consensus Rating
Moderate Buy

Company Overview

Evolus Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
85th Percentile Overall Score

EOLS MarketRank™: 

Evolus scored higher than 85% of companies evaluated by MarketBeat, and ranked 164th out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Evolus has received a consensus rating of Moderate Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.

  • Upside Potential

    Evolus has a consensus price target of $21.25, representing about 231.3% upside from its current price of $6.41.

  • Amount of Analyst Coverage

    Evolus has only been the subject of 3 research reports in the past 90 days.

  • Read more about Evolus' stock forecast and price target.
  • Earnings Growth

    Earnings for Evolus are expected to grow in the coming year, from ($0.61) to ($0.13) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Evolus is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Evolus is -6.58, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Evolus has a P/B Ratio of 71.27. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Evolus' valuation and earnings.
  • Percentage of Shares Shorted

    22.92% of the float of Evolus has been sold short.
  • Short Interest Ratio / Days to Cover

    Evolus has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Evolus has recently increased by 0.26%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Evolus does not currently pay a dividend.

  • Dividend Growth

    Evolus does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    22.92% of the float of Evolus has been sold short.
  • Short Interest Ratio / Days to Cover

    Evolus has a short interest ratio ("days to cover") of 8.7.
  • Change versus previous month

    Short interest in Evolus has recently increased by 0.26%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Evolus has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.
  • Search Interest

    6 people have searched for EOLS on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Evolus insiders have bought 376.12% more of their company's stock than they have sold. Specifically, they have bought $204,600.00 in company stock and sold $42,972.00 in company stock.

  • Percentage Held by Insiders

    Only 5.90% of the stock of Evolus is held by insiders.

  • Percentage Held by Institutions

    90.69% of the stock of Evolus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Evolus' insider trading history.
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

EOLS Stock News Headlines

Tilson: “I’m watching HOOD”
A strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fastest pace in history. CNBC calls it "the largest wealth creation spree in history." Yet 1 in 3 Americans now fear their financial situation is deteriorating. There's only one way to survive, says the man who predicted 2008 and 2020, but sadly it's already too late for many.tc pixel
Evolus Appoints Tatjana Mitchell as New CFO
See More Headlines

EOLS Stock Analysis - Frequently Asked Questions

Evolus' stock was trading at $11.04 on January 1st, 2025. Since then, EOLS stock has decreased by 41.9% and is now trading at $6.4140.

Evolus, Inc. (NASDAQ:EOLS) posted its quarterly earnings data on Tuesday, March, 23rd. The company reported ($0.44) earnings per share for the quarter, missing analysts' consensus estimates of ($0.26) by $0.18. The firm earned $20.58 million during the quarter, compared to the consensus estimate of $20.60 million. Evolus had a negative trailing twelve-month return on equity of 759.04% and a negative net margin of 22.31%.
Read the conference call transcript
.

Evolus (EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at a price of $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evolus investors own include American Water Works (AWK), Humana (HUM), Waste Connections (WCN), Voyager Therapeutics (VYGR), The RMR Group (RMR), DiamondRock Hospitality (DRH) and AU Optronics (AUOTY).

Company Calendar

Last Earnings
3/23/2021
Today
10/03/2025
Next Earnings (Estimated)
11/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED PRODUCTS
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:EOLS
CIK
1570562
Fax
N/A
Employees
170
Year Founded
2014

Price Target and Rating

High Price Target
$25.00
Low Price Target
$18.00
Potential Upside/Downside
+240.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

EPS (Trailing Twelve Months)
($0.98)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$50.42 million
Net Margins
-22.31%
Pretax Margin
-22.05%
Return on Equity
-759.04%
Return on Assets
-24.63%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.27
Quick Ratio
1.86

Sales & Book Value

Annual Sales
$266.27 million
Price / Sales
1.52
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.09 per share
Price / Book
69.33

Miscellaneous

Outstanding Shares
64,680,000
Free Float
60,869,000
Market Cap
$403.60 million
Optionable
Optionable
Beta
1.04

Social Links

7 Stocks to Ride The A.I. Megaboom Cover


We are about to experience the greatest A.I. boom in stock market history...

Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.

That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.

  1. The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
  2. The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
  3. Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.

Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.

And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...

Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.

Get This Free Report

This page (NASDAQ:EOLS) was last updated on 10/3/2025 by MarketBeat.com Staff
From Our Partners